The Pheochromocytoma drugs in development market research report provides comprehensive information on the therapeutics under development for Pheochromocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pheochromocytoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Pheochromocytoma by 17 companies/universities/institutes. The top development phase for Pheochromocytoma is phase ii with 14 drugs in that stage. The Pheochromocytoma pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Pheochromocytoma pipeline products market are: Chimerix, Ipsen and Perspective Therapeutics.
The key targets in the Pheochromocytoma pipeline products market include Somatostatin Receptor Type 2, Vascular Endothelial Growth Factor Receptor 2, and Vascular Endothelial Growth Factor Receptor.
The key mechanisms of action in the Pheochromocytoma pipeline product include Vascular Endothelial Growth Factor Receptor Inhibitor with three drugs in Phase II. The Pheochromocytoma pipeline products include six routes of administration with the top ROA being Oral and six key molecule types in the Pheochromocytoma pipeline products market including Small Molecule, and Synthetic Peptide.
Pheochromocytoma overview
Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1).
For a complete picture of Pheochromocytoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
